NCT06264180Phase 3Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-09-30Estimated

Enrollment · participants400Estimated

Source updated2026-07-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-15 · 1 field changed

Primary completion date changed

− Before

~~1 Jan 2029~~

+ After

30 Sep 2030

Check registry source

Study details

Conditions studied

Advanced Melanoma

Treatments or interventions studied

Vusolimogene OderparepvecBiologicalAlso known as VO, RP1
NivolumabBiologicalAlso known as Opdivo
Nivolumab + RelatlimabBiologicalAlso known as Opdualag
PembrolizumabBiologicalAlso known as Keytruda
Single-agent chemotherapyDrug

Primary outcomes · main study measures

measure: Overall Survival (OS); description: Time from the date of randomization to death due to any cause; timeFrame: Assessed up to January 2029, approximately 55 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history